Solventum Completes Acquisition of Acera Surgical

Solventum, a healthcare company, has successfully finalized its acquisition of Acera Surgical, a bioscience company specializing in engineered materials for regenerative wound care. The acquisition, valued at an initial $725 million with potential additional payments of up to $125 million based on future milestones, is a significant move for Solventum. The company expects the new addition to be slightly dilutive to adjusted earnings per share in 2026 but anticipates it to become accretive from 2027 onwards.

Solventum is excited to merge Acera's innovative technology with its advanced wound care portfolio, aiming to enhance its offerings to clinicians and decision-makers in acute care settings. The transaction is projected to have no significant impact on Solventum's financial results for Q4 2025, while Acera is anticipated to generate around $90 million in sales for the same year.

The acquisition was facilitated with financial advice from Morgan Stanley & Co. LLC serving as Solventum's financial advisor and legal counsel provided by McDermott Will & Schulte LLP. Truist Securities acted as financial advisor to Acera with legal guidance from Hogan Lovells US LLP.

The acquisition falls under Solventum's three-phased transformation plan and is viewed as a strategic step to accelerate growth and deliver substantial value for patients, clinicians, and shareholders. For more information on the acquisition, interested parties can refer to the announcement press release from November 20, 2025.